Journal
BIOCHEMICAL PHARMACOLOGY
Volume 174, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2019.113711
Keywords
Humanized mice; NSG; Gene therapy; Lentiviral vector; CAR T; HIV; T cell; B cell; Hematopoietic stem cell
Categories
Funding
- Association francaise contre les myopathies (AF), France
- Agence nationale de recherche sur le VIH et les hepatites virales (ANRS), France
- Fondation ARC pour la recherche sur le cancer (ARC), France
- Laboratoire d'Excellence (LABEX), France
- European Community
- INSERM
- European Union H2020 grant [SCIDNet 666908]
- INCA-Plan Cancer grant (2009-2013)
- French National Research Agency (ANR) [ANR-10-IAHU-01]
- Ministria de Economia, Comercio y Competitividad y Fondo Europeo de Desarcia Regional (FEDER) RTI 2018
Ask authors/readers for more resources
Over the last decade, incrementally improved xenograft mouse models, which support the engraftment and development of a human hemato-lymphoid system, have been developed and represent an important fundamental and preclinical research tool. Immunodeficient mice can be transplanted with human hematopoietic stem cells (HSCs) and this process is accompanied by HSC homing to the murine bone marrow. This is followed by stem cell expansion, multilineage hematopoiesis, long-term engraftment, and functional human antibody and cellular immune responses. The most significant contributions made by these humanized mice are the identification of normal and leukemic hematopoietic stem cells, the characterization of the human hematopoietic hierarchy, screening of anti-cancer therapies and their use as preclinical models for gene therapy applications. This review article focuses on several gene therapy applications that have benefited from evaluation in humanized mice such as chimeric antigen receptor (CAR) T cell therapies for cancer, anti-viral therapies and gene therapies for multiple monogenetic diseases. Humanized mouse models have been and still are of great value for the gene therapy field since they provide a more reliable understanding of sometimes complicated therapeutic approaches such as recently developed therapeutic gene editing strategies, which seek to correct a gene at its endogenous genomic locus. Additionally, humanized mouse models, which are of great importance with regard to testing new vector technologies in vivo for assessing safety and efficacy prior to clinical trials, help to expedite the critical translation from basic findings to clinical applications. In this review, innovative gene therapies and preclinical studies to evaluate T- and B-cell and HSC-based therapies in humanized mice are discussed and illustrated by multiple examples.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available